Groundbreaking Pharmacokinetic Study Initiated by Silo Pharma
In a significant step towards addressing chronic pain and fibromyalgia, Silo Pharma, Inc. has embarked on a pharmacokinetic (PK) and tolerability study. The developmental stage biopharmaceutical company is partnering with AmplifyBio, a reputable contract research organization, to analyze the effects of its innovative dissolvable, ketamine-based injectable implant known as SP-26.
Innovative Research on SP-26
SP-26 stands out as a self-administered, non-opioid therapeutic solution designed specifically for managing chronic pain. This study marks a pivotal moment for Silo Pharma, as it aims to uncover the pharmacokinetics of this implant by utilizing a minipig model, which is known for closely mimicking human responses in drug absorption and metabolism.
The non-GLP (Good Laboratory Practice) study will unfold over three weeks, meticulously investigating how the implant is absorbed, distributed, metabolized, and excreted within the body. By testing two distinct polymer formulations at varying dosages, Silo hopes to uncover crucial data that will pave the way for effective treatment options for individuals suffering from these debilitating conditions.
CEO Insights on SP-26 Development
Eric Weisblum, CEO of Silo Pharma, expressed enthusiasm regarding the advancement of SP-26 into animal testing, viewing it as a major achievement in their research efforts. "We have produced promising results from numerous studies of our SP-26 ketamine implants earlier this year, including rigorous analytical testing and small batch proof-of-concept extrusion trials," Weisblum noted. He emphasized the importance of this research in developing a safe and effective treatment to help chronic pain sufferers. This indicates the company's commitment to innovation and continuous improvement in therapeutic approaches.
Collaboration with AmplifyBio
AmplifyBio's participation is critical as it brings experience and expertise into the research endeavor. Jerry Hacker, EVP and Chief Commercial Officer, commented on the partnership, indicating the company’s dedication to executing the PK study with utmost precision and excellence. Collaborations of this nature exemplify Silo’s strategy to utilize strategic alliances for successful drug development.
Exploring SP-26's Potential
The SP-26 implant is designed to deliver controlled dosages of ketamine, providing a reliable method of pain management that circumvents the issues often associated with opioid treatments. If the studies yield positive results, SP-26 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, which accelerates the approval process for novel therapeutics.
About Silo Pharma: Vision and Future Directions
Silo Pharma, Inc. is not only focusing on SP-26; its commitment extends across various therapeutic avenues, specifically targeting conditions that currently lack effective treatment options. From addressing stress-induced psychiatric disorders to chronic pain conditions, Silo Pharma is pioneering methodologies in both psychedelic and traditional drug formulations.
The company’s main program, SPC-15, engages with PTSD and anxiety disorders through an intranasal approach. Further, their preclinical projects include SPC-14 for Alzheimer’s disease treatment and SPU-16 focusing on multiple sclerosis. Such diverse initiatives underline Silo's mission to bring forth innovations in pharmaceuticals through integrative research and development.
Frequently Asked Questions
What is SP-26?
SP-26 is a dissolvable ketamine-based polymer implant intended for the treatment of chronic pain and fibromyalgia.
Why is the study on SP-26 important?
The study will provide insights into the pharmacokinetics of SP-26, which are crucial for developing effective pain management therapies.
What are the expected outcomes from the pharmacokinetic study?
The study aims to assess the absorption, distribution, metabolism, and excretion of the SP-26 implant to ensure its efficacy and safety.
How does Silo Pharma's approach differ from traditional pain treatments?
Silo Pharma’s SP-26 aims to deliver a non-opioid treatment option that provides sustained pain relief, potentially reducing dependency on opioids.
What other projects is Silo Pharma working on?
Beyond SP-26, Silo Pharma is developing treatments for PTSD, anxiety, Alzheimer’s disease, and multiple sclerosis through innovative drug delivery systems.
